Opus Genetics IRD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $11.98M-12.2% | $14.2M+29.1% | $14.63M+74.6% | $15.42M-6.2% | $13.65M-28.2% | ||
| —— | —— | —— | —— | —— | ||
| $21.58M+8.5% | $21.98M+20.7% | $24.39M+71.8% | $22.3M+67.0% | $19.89M+38.7% | ||
| $55.02M-29.4% | $52.8M-27.7% | $79.81M+111% | $80.29M+155% | $77.95M+150% | ||
| -$43.03M+33.1% | -$38.6M+37.8% | -$65.18M-121% | -$64.87M-330% | -$64.3M-430% | ||
| -359.1%+112pp | -271.9%+293pp | -445.4%-93.7pp | -420.7%-329pp | -471%-407pp | ||
| $198K— | $129K— | $68K— | $0— | $0— | ||
| $2.53M-39.3% | $1.99M-55.5% | $4.11M+81.7% | $4.14M+85.4% | $4.17M+98.7% | ||
| -$106.93M-82.4% | -$49.59M+13.8% | -$68.2M-151% | -$58.28M-314% | -$58.62M-419% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$106.93M-82.4% | -$49.59M+13.8% | -$68.2M-151% | -$58.28M-313% | -$58.62M-419% | ||
| -892.4%-463pp | -349.3%+174pp | -466.1%-142pp | -377.9%-292pp | -429.4%-370pp | ||
| -$1.33+36.7% | -$0.82+61.9% | -$1.88-72.5% | -$1.92-249% | -$2.10-329% | ||
| -$42.98M+33.1% | -$38.55M+37.9% | -$65.13M-121% | -$64.84M-330% | -$64.27M-430% | ||
| -358.7%+112pp | -271.5%+293pp | -445.1%-93.4pp | -420.4%-329pp | -470.8%-407pp | ||
| -$43.03M+33.1% | -$38.6M+37.8% | -$65.18M-121% | -$64.87M-330% | -$64.3M-430% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Opus Genetics's revenue?
- Opus Genetics (IRD) generated $12.0M in revenue over the trailing twelve months, down 12.2% year over year.
- Is Opus Genetics profitable?
- Opus Genetics is not currently profitable: it reported a net loss of $106.9M over the trailing twelve months, a -892.4% net margin.
- What is Opus Genetics's earnings per share?
- Opus Genetics's diluted EPS over the trailing twelve months is $-1.33.
- Where does Opus Genetics's income statement data come from?
- Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
